Carma Fund is a venture capital firm that focuses on early-stage investments in the life science and healthcare sectors, including therapeutics, diagnostics, platform technologies, medical technology, and digital health. Their strategy involves supporting high-potential startups and projects, primarily in Germany, with a long-term investment horizon of 15+ years, often in Seed rounds.
60% of their portfolio is in Enterprise Software. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Their most common stage is series-b (60% of deals). Average disclosed round size is $33.3M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
$300M
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Exciva | Series B | $59M | Jan 2026 |
 Elkedonia | Seed | $12.2M | Jun 2025 |
| EExciva GmbH | Series B | $59M | Jan 2025 |
 Aignostics | Series B | $34M | Oct 2024 |
 Symphera | Seed | $2.5M | Sep 2024 |
Top Co-Investors
Gimv2 shared
EQT Life Sciences2 shared
Fountain Healthcare2 shared
LifeArc Ventures2 shared
Andera Partners2 shared
LBBW Venture Capital2 shared
HTGF2 shared
Wellington Management1 shared
ATHOS1 shared
Mayo Clinic1 shared
Boehringer Ingelheim Venture Fund1 shared
Kurma Partners1 shared
Angelini Ventures1 shared
Capital Grand Est1 shared
Bpifrance1 shared
Bayern Kapital1 shared
UnternehmerTUM Funding for Innovators1 shared
Last updated: 7 April 2026